Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 14/20 | 0.85 |
| ▸ | CTNNB1 | P35222 | 14/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165094 | 0.93 | BCL9 (0.98) | BCL9CTNNB1HTR2ASUCNR1PLAU | |
| SCHEMBL18165095 | 0.90 | BCL9 (0.98) | BCL9CTNNB1HTR2ASUCNR1PLAU | |
| SCHEMBL20021897 | 0.89 | BCL9 (0.89) | BCL9CTNNB1HTR2APLAUMCHR1 | |
| SCHEMBL18152394 | 0.84 | BCL9 (0.82) | BCL9CTNNB1MCHR1 | |
| SCHEMBL18165096 | 0.84 | BCL9 (0.98) | BCL9CTNNB1HTR2AMCHR1KDR | |
| SCHEMBL20021887 | 0.83 | CTNNB1 (0.78) | BCL9CTNNB1HTR2APLAU | |
| SCHEMBL20021894 | 0.83 | BCL9 (0.82) | BCL9CTNNB1HTR2APLAUMCHR1 | |
| SCHEMBL20021886 | 0.83 | BCL9 (0.84) | BCL9CTNNB1HTR2APLAUKDR | |
| SCHEMBL20021880 | 0.82 | BCL9 (0.83) | BCL9CTNNB1 | |
| SCHEMBL18152322 | 0.82 | BCL9 (0.82) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 4/4885HTR2A 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.